208 related articles for article (PubMed ID: 31637004)
1. Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.
Zheng H; Tie Y; Fang Z; Wu X; Yi T; Huang S; Liang X; Qian Y; Wang X; Pi R; Chen S; Peng Y; Yang S; Zhao X; Wei X
Signal Transduct Target Ther; 2019; 4():24. PubMed ID: 31637004
[TBL] [Abstract][Full Text] [Related]
2. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
Lee YF; Miller LD; Chan XB; Black MA; Pang B; Ong CW; Salto-Tellez M; Liu ET; Desai KV
Breast Cancer Res; 2012 May; 14(3):R85. PubMed ID: 22621393
[TBL] [Abstract][Full Text] [Related]
3. A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo.
Xiao RQ; Ran T; Huang QX; Hu GS; Fan DM; Yi J; Liu W
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2200753119. PubMed ID: 35969736
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of N-(1-(6-(substituted phenyl)-pyridazin-3-yl)-piperidine-3-yl)-amine derivatives as JMJD6 inhibitors.
Qian Y; Ao M; Li B; Kuang Z; Wang X; Cao Y; Li J; Qiu Y; Guo K; Fang M; Wu Z
Bioorg Chem; 2022 Dec; 129():106119. PubMed ID: 36116323
[TBL] [Abstract][Full Text] [Related]
5. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.
Zhang Z; Yang Y; Zhang X
Life Sci; 2017 Nov; 188():163-171. PubMed ID: 28882645
[TBL] [Abstract][Full Text] [Related]
6. LINC00839/miR-519d-3p/JMJD6 axis modulated cell viability, apoptosis, migration and invasiveness of lung cancer cells.
Yu X; Jiang Y; Hu X; Ge X
Folia Histochem Cytobiol; 2021; 59(4):271-281. PubMed ID: 34734406
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6.
Ge X; Jiang Y; Hu X; Yu X
Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003
[TBL] [Abstract][Full Text] [Related]
8. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
9. JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component.
Liu X; Si W; Liu X; He L; Ren J; Yang Z; Yang J; Li W; Liu S; Pei F; Yang X; Sun L
Mol Cancer; 2017 Nov; 16(1):175. PubMed ID: 29187213
[TBL] [Abstract][Full Text] [Related]
10. JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation.
Wang F; He L; Huangyang P; Liang J; Si W; Yan R; Han X; Liu S; Gui B; Li W; Miao D; Jing C; Liu Z; Pei F; Sun L; Shang Y
PLoS Biol; 2014 Mar; 12(3):e1001819. PubMed ID: 24667498
[TBL] [Abstract][Full Text] [Related]
11. Jumonji domain-containing protein 6 functions as a marker of head and neck squamous cell carcinoma at advanced stage with no effect on prognosis.
Guo B; Wang L; Qin X; Shen Y; Ma C
Oncol Lett; 2019 Dec; 18(6):5843-5852. PubMed ID: 31788057
[TBL] [Abstract][Full Text] [Related]
12. Role of JMJD6 in Breast Tumourigenesis.
Poulard C; Rambaud J; Lavergne E; Jacquemetton J; Renoir JM; Trédan O; Chabaud S; Treilleux I; Corbo L; Le Romancer M
PLoS One; 2015; 10(5):e0126181. PubMed ID: 25951181
[TBL] [Abstract][Full Text] [Related]
13. Genomic structure and expression of Jmjd6 and evolutionary analysis in the context of related JmjC domain containing proteins.
Hahn P; Böse J; Edler S; Lengeling A
BMC Genomics; 2008 Jun; 9():293. PubMed ID: 18564434
[TBL] [Abstract][Full Text] [Related]
14. High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma.
Zhang J; Ni SS; Zhao WL; Dong XC; Wang JL
Tumour Biol; 2013 Aug; 34(4):2397-401. PubMed ID: 23595221
[TBL] [Abstract][Full Text] [Related]
15. JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.
Wan J; Liu H; Yang L; Ma L; Liu J; Ming L
Int J Cancer; 2019 May; 144(10):2489-2500. PubMed ID: 30125344
[TBL] [Abstract][Full Text] [Related]
16. JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
Wong M; Sun Y; Xi Z; Milazzo G; Poulos RC; Bartenhagen C; Bell JL; Mayoh C; Ho N; Tee AE; Chen X; Li Y; Ciaccio R; Liu PY; Jiang CC; Lan Q; Jayatilleke N; Cheung BB; Haber M; Norris MD; Zhang XD; Marshall GM; Wang JY; Hüttelmaier S; Fischer M; Wong JWH; Xu H; Perini G; Dong Q; George RE; Liu T
Nat Commun; 2019 Jul; 10(1):3319. PubMed ID: 31346162
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of JMJD6 expression reduces the proliferation, migration and invasion of neuroglioma stem cells.
Zhou DX; Zhou D; Zhan SQ; Wang P; Qin K; Gan W; Lin XF
Neoplasma; 2017; 64(5):700-708. PubMed ID: 28592121
[TBL] [Abstract][Full Text] [Related]
18. JMJD6 functions as an oncogene and is associated with poor prognosis in esophageal squamous cell carcinoma.
Liu H; Jiang M; Ma F; Qin J; Zhou X; Xu L; Yan X; Jiang T
BMC Cancer; 2023 Jul; 23(1):696. PubMed ID: 37488513
[TBL] [Abstract][Full Text] [Related]
19. Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response.
Wang K; Yang C; Li H; Liu X; Zheng M; Xuan Z; Mei Z; Wang H
Front Immunol; 2022; 13():859893. PubMed ID: 35359945
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a new class of JMJD6 inhibitors and structure-activity relationship study.
Wang T; Zhang R; Liu Y; Fang Z; Zhang H; Fan Y; Yang S; Xiang R
Bioorg Med Chem Lett; 2021 Jul; 44():128109. PubMed ID: 33991627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
